Furthermore, treatment of patient ALCL cells expressing the TRAF1-ALK fusion protein with proteasome inhibitors that decrease NF-κB1/2 or a selective ALK inhibitor (CEP28122) results in significant inhibition on lymphoma growth but could not eradicate lymphoma cells (18). This evidence concerns the gene ALK and lymphoma.